A summary of the completed phase II and III trials utilizing epidermal growth factor receptor type two (HER2)-targeting tyrosine kinase inhibitors in the management of HER2-positive gastric cancer and gastroesophageal cancer. This evidence concerns the gene ERBB2 and gastric cancer.